QS-21

O[C@H]1COC[C@@H](O)[C@@H]1O.O[C@H]2COC[C@]2(O)CO.O[C@H]([C@@H]([C@H]([C@@H](O3)C)O[C@H]4[C@@H]([C@H]([C@@H](CO4)O)O[R])O)O)[C@@H]3O[C@H]([C@H]([C@H]([C@H](O5)C)OC(C[C@@H](O)C[C@H](OC(C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@@H]6O[C@H]([C@@H]([C@H]6O)O)CO)=O)[C@H](CC)C)=O)O)[C@@H]5OC([C@]78[C@](CC(C)(CC8)C)([H])C9=CC[C@@]([C@@]%10([C@@]([C@@](C)([C@H](CC%10)O[C@H]%11[C@@H]([C@H]([C@@H]([C@H](O%11)C(O)=O)O)O[C@H]%12[C@@H]([C@H]([C@@H](CO%12)O)O)O)O[C@@H]%13O[C@@H]([C@@H]([C@@H]([C@H]%13O)O)O)CO)C=O)([H])CC%14)C)([H])[C@]%14(C)[C@@]9(C[C@H]7O)C)=O.[35%].[65%]

[1]Deng K, et al. Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine. Angew Chem Int Ed Engl. 2008;47 (34) :6395-8.